<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365875">
  <stage>Registered</stage>
  <submitdate>24/04/2014</submitdate>
  <approvaldate>2/05/2014</approvaldate>
  <actrnumber>ACTRN12614000462684</actrnumber>
  <trial_identification>
    <studytitle>The effect of Glycomax 'Trademark' lactoferrin and bovine whey immunoglobulin-rich fraction on gene expression patterns in healthy adults: a double-blind placebo-controlled randomised clinical trial </studytitle>
    <scientifictitle>In healthy adults do Glycomax 'Trademark' lactoferrin and bovine whey immunoglobulin-rich fraction supplements influence gene expression patterns?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immune Function in Healthy Adults</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Supplementation for 28 days with oral supplements once daily from one of six possible treatments
Arm 1: Lactoferrin 200mg 
Arm 2: Whey Ig-rich Fraction 200mg
Arm 3: Whey Ig-rich Fraction 800mg
Arm 4: Lactoferrin 200mg + Whey Ig-rich fraction 200mg
Arm 5: Lactoferrin 200mg + Whey Ig-rich faction 800mg
Arm 6: Placebo

Compliance will be encouraged with a daily checklist and monitored by supplement return at the end of the intervention period.</interventions>
    <comparator>Placebo (mannitol and calcium carbonate based tablets)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in whole genome gene expression patterns (determined using expression arrays) in response to the intervention.</outcome>
      <timepoint>Intervention period is 28 days.
Primary endpoints will be determined at day 28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Self-reported illness symptoms reported via the Wisconsin Upper Respiratory Symptom Survey-11</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For inclusion into the study, participants are required to be:
aged between 18-55 years;
in current good health;
have Body Mass Index (BMI) &lt;30 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Participants will be excluded from participation if they:
are lactose intolerant;
consume of fish oil, probiotics, prebiotics, whey protein supplements during the trial period;
require insulin use (for treatment of diabetes);
have a history of liver, kidney or thyroid disease;
use anti-inflammatory or immune-modulating medications; have heavy alcohol consumption (according to the CDC definitions);
are pregnant or intending to become pregnant during the trial period;
have had high level of radiation exposure over the preceding 12 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be randomly allocated to one of six treatment groups using simple block randomization. Groups will be coded numerically and the allocation code concealed from the research team in sealed envelopes for the duration of the trail.  </concealment>
    <sequence>Given the multiple treatment arms in this trial, simple block randomisation will be used for subject allocation. This involves ordering the six treatment groups in a series of randomly sequenced repeating blocks. Consecutively recruited participants are then allocated to a group based on the sequence of the current block. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/06/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Griffith University</primarysponsorname>
    <primarysponsoraddress>Gold Coast Campus
University Drive 
Southport
QLD 4222</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Probiotec Pharma Pty Ltd</fundingname>
      <fundingaddress>83 Cherry Lane
Laverton North
VIC 3026</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Growing research into the effects of several whey-derived proteins (cows milk proteins) suggests that bovine lactoferrin and immunonglobulins may have a number of health benefits for consumers including improved metabolic and immune regulation. This study aims to examine any link between bovine lactoferrin and immunoglobulin consumption and gene expression patterns which may reveal which biological pathways are involved in driving responses to these supplements.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Griffith University Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Bray Center N54_0.15
Griffith University - Nathan Campus
Kessels Road
Nathan 4111
QLD</ethicaddress>
      <ethicapprovaldate>12/02/2014</ethicapprovaldate>
      <hrec>MED/32/13/HREC</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Allan Cripps</name>
      <address>Griffith University
Gold Coast Campus
PVCH (G40 Level 8)
Parklands Drive
Southport
QLD 4222</address>
      <phone>+6 17 5678 0795</phone>
      <fax />
      <email>allan.cripps@griffith.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicholas West</name>
      <address>Griffith University
Gold Coast Campus
G40_9.17
Parklands Drive
Southport
QLD 4222</address>
      <phone>+6 17 5678 0899</phone>
      <fax />
      <email>n.west@griffith.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amanda Cox</name>
      <address>Griffith University
Gold Coast Campus
G40_9.17
Parklands Drive
Southport
QLD 4222</address>
      <phone>+6 17 5678 0898</phone>
      <fax />
      <email>a.cox@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amanda Cox</name>
      <address>Griffith University
Gold Coast Campus
G40_9.17
Parklands Drive
Southport
QLD 4222</address>
      <phone>+6 17 5678 0898</phone>
      <fax />
      <email>a.cox@griffith.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>